Skip to content

Voice-activated and Touchscreen-controlled Smart Speaker Intervention for Older Adults With Poorly Controlled Type 2 Diabetes

Voice-activated and Touchscreen-controlled Smart Speaker Intervention for Older Adults With Poorly Controlled Type 2 Diabetes

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07734259
Acronym
VATC-SS
Enrollment
30
Registered
2026-07-29
Start date
2026-09-01
Completion date
2028-03-30
Last updated
2026-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Diabetes (DM), Type 2 Diabetes

Brief summary

This is a pre-post pilot study that will test the feasibility and acceptability of a health educator delivered diabetes education and skills training intervention using a voice-activated, touch screen controlled, smart speaker. We will enroll 30 adults aged 50 and older with poorly controlled type 2 diabetes as defined by a hemoglobin A1C of 8% in the study.

Interventions

BEHAVIORALVATC-SS Intervention

Individuals in the VATC-SS intervention will receive weekly diabetes education and skills training calls for 12 weeks from a health educator through the voice-activated, touch screen controlled smart speaker.

Sponsors

Medical College of Wisconsin
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 1\) Aged 50 and older; 2) clinical diagnosis of poorly controlled type 2 diabetes, defined as HbA1C greater than or equal to 8% at the screening visit; 3) willing to install and use the VATC-SS for the 3 months of the study.

Exclusion criteria

* 1\) Mental confusion at screening assessment suggesting significant dementia; 2) alcohol or drug abuse/dependency at screening assessment; 3) active psychosis or acute mental disorder at screening assessment.

Design outcomes

Primary

MeasureTime frameDescription
HemoglobinA1CBaseline and 3-months post enrollmentAbout 10cc of blood will be drawn by phlebotomist and sent to the lab for testing
Blood PressureBaseline and 3-months post-enrollmentBlood pressure readings will be obtained using automated blood pressure monitors (OMRON IntelliSenseTM HEM-907 XL). The device will be programmed to take 3 readings at 2-minute intervals and give an average of the 3 blood pressure readings.
Low-Density Lipoprotein CholesterolBaseline and 3-months post-enrollmentAbout 10cc of blood will be drawn by phlebotomist and sent to the lab for testing

Secondary

MeasureTime frameDescription
DepressionBaseline and 3-months post-enrollmentDepression will be measured using the 9-item Patient Health Questionnaire (PHQ-9)
Social IsolationBaseline and 3-months post-enrollmentThe PROMIS Short Form v2.0 - Social Isolation 8a will be used to measure social isolation
LonelinessBaseline and 3-months post-enrollmentThe five-item Loneliness Fixed form from the NIH Toolbox Item Bank v3.0 for adults will be used to assess loneliness

Contacts

CONTACTAprill Z Dawson, PhD, MPH
adawson@mcw.edu414-955-8828

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 30, 2026